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Abstract
Background Four randomized controlled trials have
demonstrated the short-term efficacy and safety of transoral
esophagogastric fundoplication (TF) performed with the
EsophyX device in eliminating troublesome gastroe-
sophageal reflux disease (GERD) symptoms in well-se-
lected patient populations. The aim of this study was to
assess the durability of these outcomes at 3 years post-
procedure.
Methods The TF EsophyX versus Medical PPI Open Label
trial was conducted in seven US sites. Between June and
August 2012, we enrolled patients with small (\2 cm) or
absent hiatal hernias who suffered from troublesome
GERD symptoms while on PPI therapy for at least
6 months and had abnormal esophageal acid exposure
(EAE). Randomization was to TF group (n = 40) or to PPI
group (n = 23). Following evaluation at 6 months, all
remaining PPI patients (n = 21) elected to undergo
crossover to TF. Fifty-two patients were assessed at 3 years
for (1) GERD symptom resolution using three GERD-
specific quality of life questionnaires, (2) healing of
esophagitis using endoscopy, (3) EAE using 48-h Bravo
testing, and (4) discontinuation of PPI use. Two patients
who underwent revisional procedures by year 3 were
included in the final analysis.
Results At 3-year follow-up, elimination of troublesome
regurgitation and all atypical symptoms was reported by
90 % (37/41) and 88 % (42/48) of patients, respectively.
The mean Reflux Symptom Index score improved from
22.2 (9.2) on PPIs at screening to 4 (7.1) off PPIs 3 years
post-TF, p\ 0.0001. The mean total % time pH \4
improved from 10.5 (3.5) to 7.8 (5.7), p = 0.0283.
Esophagitis was healed in 86 % (19/22) of patients. At the
end of study, 71 % (37/52) of patients had discontinued
PPI therapy. All outcome measures remained stable be-
tween 1-, 2-, and 3-year follow-ups.
Conclusion This study demonstrates that TF can be used to
achieve long-term control of chronic GERD symptoms,
healing of esophagitis, and improvement in EAE.
Keywords GERD  TIF  Heartburn  Transoral
fundoplication  Regurgitation  Atypical symptoms
Gastroesophageal reflux disease (GERD) is a chronic and
often progressive condition that develops when the
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and Other Interventional Techniques 
retrograde flow of gastric contents into the upper aerodi-
gestive tract causes troublesome symptoms and related
complications [1]. It is estimated that 20 % of the Western
world’s population is afflicted by various degrees of GERD
[2, 3]. Along with lifestyle modifications and over-the-
counter remedies, proton-pump inhibitors (PPIs) are cur-
rently the mainstay of medical therapy and are particularly
effective in controlling troublesome heartburn. However,
recent studies have raised public concern relating to the
potential development of osteoporosis [4], kidney disease
[5], and dementia [6] with the continuous use of PPIs over
the course of several years. Furthermore, and despite the
unquestionable effectiveness of PPIs in the majority of
cases, approximately 30–40 % of patients remain unsatis-
fied because of incomplete symptom control on optimized
PPI regimens [7]. Patients and referring gastroenterologists
are often reluctant to consider surgery as an option because
of the occasional occurrence of debilitating post-fundopli-
cation side effects [8, 9], which may account for the steady
decline in the number of laparoscopic Nissen fundoplica-
tions (LNF) performed in the past two decades [10].
In this context, the transoral esophagogastric fundopli-
cation (TF) performed with the EsophyX device (Red-
mond, Washington) has emerged as a viable endoscopic
alternative to conventional medical and surgical treatments
of chronic GERD. The TF procedure creates a full-thick-
ness, partial esophagogastric fundoplication above the Z-
line, with fastener fixations extending longitudinally up to
3.5 cm and circumferentially between 270 and 330 [11].
Published randomized controlled multicenter double-blind
and open-label studies have demonstrated the superiority of
the TF procedure as compared to high-dose PPI therapy
and/or sham procedure in eliminating troublesome regur-
gitation and a range of classic and atypical manifestations
of chronic GERD up to 12 months post-TF in subgroups of
patients with hiatal hernias B2 cm [12–15]. Importantly, in
more than 17,000 procedures performed to date, TF has
maintained a solid safety record with virtual absence of
associated new onset of dysphagia and gas bloat [12–15].
However, due to the lack of long-term follow-up data from
the USA, the durability of the therapeutic effects following
TF has remained in question.
The 3-year follow-up data from the TIF EsophyX versus
Medical PPI Open Label (TEMPO) randomized trial (clin
icaltrials.gov: NCT01647958), which are the subject of this
report, offer the opportunity to explore the long-term
effects and durability of TF. We analyze the variations in
symptom control, healing of esophagitis, cessation of PPIs,
and amounts of distal esophageal acid exposure (EAE)
between baseline and at three time intervals: 1, 2, and
3 years post-procedure. To the best of our knowledge, the
current study represents the longest reported follow-up for
chronic GERD patients receiving the TF procedure in the
USA.
Methods
Study design and oversight
Enrollment and follow-up of patients for the TEMPO
randomized trial with a crossover arm was conducted at
seven US centers from June 2012 through August 2015.
The study design has been described previously [14, 15].
The trial was sponsored by the manufacturer of the Eso-
phyX device which was used in performing the TF pro-
cedure. A protocol development team led by K. Trad
designed the TEMPO study in collaboration with the
sponsor. The trial protocol was approved by the institu-
tional review board at each participating center. Data were
collected by the investigators and coordinators at each site
and entered into the secure electronic data capture system.
As required by good clinical practices and applicable reg-
ulations, the sponsor of the trial was involved in source
verification of the data (i.e., the comparison of reported
trial data with information from primary health records of
trial subjects). The first author wrote the initial draft of the
manuscript, and revisions were made by all the authors.
The study investigators vouch for the accuracy and com-
pleteness of the data and of all analyses.
Patients
Patients 18 years of age or older who were experiencing
daily troublesome regurgitation or extra-esophageal mani-
festations of GERD while on daily PPI therapy and who
had abnormal EAE off PPI therapy (defined as pH\4 for
more than 5.3 % of total recorded time using 48-h Bravo
pH testing) were deemed eligible for the study [14].
Excluded were patients those who presented with a hiatal
hernia larger than 2 cm in axial length or greatest trans-
verse dimension, reflux esophagitis grade C or D (Los
Angeles classification), Barrett’s esophagus [2 cm, eso-
phageal ulcer or fixed esophageal strictures or narrowing.
Additionally, patients with motility disorders and previous
gastric or esophageal surgery were also excluded [14].
At the time of enrollment, patients were required to have
a documented history of daily PPI use for at least 6 months
and a confirmed diagnosis of GERD for at least 1 year. All
participating patients provided written informed consent.
Study procedures
Patients meeting eligibility criteria were randomly
assigned, in a 2:1 ratio, to undergo TF (TF group) or to
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receive high-dose PPI therapy (PPI group). A computer-
generated block sequence randomization of nine was used,
and randomization was stratified according to study center
[14, 15]. At 6-month follow-up assessment, all patients
from the PPI group elected to undergo crossover to TF. We
have previously reported data from the 6-month follow-up
(comparing TF vs. high-dose PPI therapy) [14] and the
12-month follow-up (assessing durability of TF up to
12 months and assessing clinical outcomes 6 months post-
TF in crossover patients) [15]. For the purpose of this
study, we combined patients from the initial TF group and
crossover group and assessed for durability of TF up to
3 years post-procedure. Clinical evaluation of all study
patients was performed at the prespecified study intervals
and according to the study protocol (Table 1).
The performance of the standard TF 2.0 procedure was
mandated by the study protocol for all study patients who
underwent TF [14]. All TF procedures were performed
using the EsophyX device under general endotracheal
anesthesia. The device is introduced transorally over a
flexible endoscope and inserted into the stomach under
constant endoscopic visualization. The endoscope is ret-
roflexed to provide visualization of the gastroesophageal
junction (GEJ). The helical retractor is engaged into the
tissue just below the Z-line. The fundus of the stomach is
then folded up and wrapped around the distal esophagus
utilizing the tissue mold, the chassis, and the helix as an
anchor. After locking all the tissue-manipulating elements,
the invaginator is activated to allow the advancement of the
GEJ below the diaphragm. Polypropylene ‘‘H’’ fasteners
are then delivered through the thickness of the apposed
stomach and esophageal walls. The maneuver is repeated at
three additional positions to create a full-thickness, partial
gastroesophageal fundoplication, with an average of 21
fasteners deployed at various locations. Intraoperative
endoscopy is performed immediately before and after
introducing the EsophyX device to assess the GEJ, confirm
Hill grade, and assess the size of hiatal hernia, if present.
Patients were followed up for a maximum of 3 years
post-TF. Following the last study visit conducted in
September 2015, data were monitored for accuracy against
source documents.
Outcomes and effectiveness assessment
The primary outcome measure of the TEMPO trial was
elimination of daily troublesome regurgitation and atypical
symptoms, as defined by the Montreal consensus [1]. The
Reflux Disease Questionnaire (RDQ) was used to assess
frequency and severity of regurgitation; the Reflux Symp-
tom Index (RSI) questionnaire was used to assess atypical
GERD symptoms. RDQ is a 12-item questionnaire that was
designed to assess the frequency and severity of heartburn
(four items measuring the frequency and severity of pain
and burning behind the breastbone), regurgitation (four
items measuring the frequency and severity of acid taste in
the mouth and movement of the material upward from the
stomach), and dyspeptic complaints (four items measuring
the frequency and severity of pain or burning in the upper
stomach) [16]. Response options range from 0 (not present)
to 5 (daily) for frequency and 0 (not present) to 5 (severe)
for severity. Each patient’s score is calculated as the mean
of item responses with higher scores indicating more fre-
quent or severe symptoms. Troublesome symptoms are
defined as mild symptoms, occurring 2 or more days a
week, or moderate to severe symptoms, occurring more
than 1 day a week [1]. The elimination of troublesome
regurgitation was evaluated with the RDQ. A frequency
score of three or more and severity score of two or more for
the regurgitation questions were required to meet the
Table 1 Evaluation protocol for patients enrolled in the study
Time interval Symptomatic assessment Esophagogastroduodenoscopy 48-h pH metry
On PPIs Off PPIs On PPIs Off PPIs On PPIs Off PPIs
Screening (all patients) X X X X
6 months post-TF X X X X
6 months after high-dose PPIs and before crossover X X X
1-year follow-up Xa X X X
2-year follow-up Xa X X X
3-year follow-up Xa X X X
All patients who were initially randomized to undergo high-dose PPI therapy underwent crossover to transoral fundoplication after completing
their 6-month follow-up
PPIs proton-pump inhibitors, TF transoral fundoplication
a Minority of patients who were back on PPIs
Surg Endosc
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Montreal consensus criteria for troublesome regurgitation
[13]. RSI is a 9-item validated questionnaire used to
measure atypical GERD symptoms such as hoarseness,
throat clearing, excess throat mucus, dysphagia, and cough
[17]. The scale for each individual item ranges from 0 (no
problem) to 5 (severe problem), with a maximum total
score of 45 and a normality threshold of B13.
Primarily, we assessed symptom control after the TF
procedure with these questionnaires while patients were off
PPIs at 1-, 2-, and 3-year intervals. Secondarily, in order to
include data on patients who had resumed PPIs after TF
and whose questionnaires were completed only while on
PPIs, we also report symptom control regardless of PPI use
(off or on PPI therapy).
Secondary outcomes included elimination of heartburn,
healing of reflux esophagitis, cessation of PPI use,
improvement in distal EAE, and patient satisfaction.
Elimination of troublesome heartburn was assessed using
the GERD health-related quality of life questionnaire
(GERD-HRQL). GERD-HRQL is designed and validated
to evaluate typical GERD symptoms by measuring ten
items (six related to heartburn, two to dysphagia, one to
bloating, and one to the impact of medications on daily
life) on the visual analog scale ranging from 0 (no symp-
toms) to 5 (worst symptoms) [18]. A higher total GERD-
HRQL score (range from 0 to 50) indicates more severe
GERD [19]. We used endoscopy to assess and grade reflux
esophagitis, if present. Complete cessation of PPI use was
documented. Levels of distal EAE were assessed with 48-h
Bravo pH monitoring, using percent total recorded time pH
\4 as our main outcome measure, and considering 5.3 %
as the threshold for normality. Patient satisfaction with
their current health condition was reported as part of the
GERD-HRQL, with three possible answers: satisfied,
neutral, or dissatisfied.
Statistical methods
The primary analysis in this report focuses on the stability
of elimination of troublesome GERD symptoms up to
3 years following the TF procedure. The comparison
within patients was made with the use of the repeated-
measures analysis of variance (ANOVA) statistical test
followed by post hoc Tukey–Kramer honestly significant
difference multiple comparison procedure to identify
which means differed from each other. In general, means
and standard deviations (SD) are reported; the study fol-
low-up intervals were reported as medians (ranges). Counts
and proportions for the categorical data were compared
with the use of McNemer’s test. The two patients who
underwent revisional procedure (TF failure) were included
in the analyses and were assigned the worst outcomes
observed during the study from the timing of revisional
procedure going forward. All analyses were performed
using JMP 11.0 statistical software. p value \0.05 was
considered significant.
Results
Between June and August 2012, 63 chronic GERD patients
were randomized (Fig. 1). Of these 63 patients, 60 (95 %)
were available for analysis at 1 year; 55 (87 %) completed
the 2-year assessment; and 52 (83 %) were available for
the 3-year data collection. Before randomization, the
average duration of GERD symptoms was 11.2 (9.8) years
and the average PPI therapy duration was 8.6 (6.5) years
(Table 2). Median time (range) post-TF was 11.2
(4.7–14.5), 22.8 (16.3–25.2), and 34.0 (27.0–37.0) months
for the 1-, 2-, and 3-year follow-up intervals, respectively.
Safety and procedure data
As previously reported, there were no serious adverse
events (SAE) such as bleeding, abdominal or thoracic
infections, or any other complication associated with the
TF procedure [14, 15]. In this study cohort, a mean of 21
(4) fasteners were used to create valves with a mean length
of 2.8 (0.5) cm and a circumference of 290 (20) as
assessed by the immediate post-procedure endoscopy.
Ninety-five percent (57/60) of patients were released from
the hospital within 24 h post-procedure. All 52 hiatal
hernias were reduced with Hill grade II (n = 49) converted
Fig. 1 Study flowchart of treated and analyzed patients. Of the 85
patients not meeting eligibility criteria, 48 % (38/85) had normal pH
test, 36 % (31/85) had hiatal hernia[2 cm in axial length or greatest
transverse dimension, 13 % had Hill grade[ II, 2 % had reflux
esophagitis[ grade B (Los Angeles classification), 2 % had body




to Hill grade I in all patients. The rate of revisional surgery
in this study was 3 % (2/60, Fig. 1) up to 3-year follow-up.
Primary outcomes
Elimination of troublesome regurgitation, as evaluated by
the RDQ, was observed in 90 % (37/41) of patients at the
3-year assessment. Similar findings were observed at 2-
(90 %, 41/44) and 1-year follow-up (88 %, 42/48). Elimi-
nation of troublesome regurgitation was further supported
by improvement in the total regurgitation scores from 3.0
on PPIs at screening to 0.5 off PPIs 3 years post-procedure,
p\ 0.0001 (Fig. 2A). Improvement in the total RDQ score
observed at 1-year follow-up remained stable between 2-
and 3-year follow-ups (Fig. 2B).
Elimination of all troublesome atypical symptoms (RSI
score B13) was observed in 82 % (45/55) at 1-, 84 % (43/
51) at 2-, and 88 % (42/48) at 3-year follow-up. Total RSI
score improved from 22.2 (9.2) on PPIs at screening to 4
(7.1) off PPIs at 3-year follow-up, p\ 0.0001 (Fig. 3). As
was observed with total RDQ scores (Fig. 2B), total RSI
scores showed no statistical difference in the means
between 1-, 2-, and 3-year follow-ups, regardless of PPI
use at the time the questionnaire was collected (off PPIs or
on/off PPIs) (Fig. 3). Means of total symptom scores, as
evaluated by the RSI questionnaires at the study intervals,
are shown in Table 3. Global elimination of regurgitation
and all atypical symptoms off PPIs was achieved in 83 %
(48/58) of patients at 1, 82 % (42/51) at 2, and 83 % (34/
41) at 3 years post-TF.
Secondary outcomes
GERD-HRQL improved from 26.4 (9.4) on PPIs at
screening to 5.0 (9.2) off PPIs at 3-year follow-up,
p\ 0.0001. There was no statistical difference between the
total GERD-HRQL score at 1-, 2-, and 3-year follow-ups
(Fig. 4).
Table 2 Baseline
characteristics of study patients
Characteristics Study cohort (n = 60)
Female, n (%) 33 (55)
Age, years, mean (SD) 51.5 (10.3)
\50, n (%) 24 (40)
50–65, n (%) 31 (52)
[65, n (%) 5 (8)
Body mass index (kg/m2), mean (SD) 28.5 (3.7)
Gastroesophageal reflux disease (GERD) symptom duration (years), mean (SD) 11.2 (9.8)
Proton-pump inhibitor (PPI) therapy duration (years), mean (SD) 8.6 (6.5)
Barrett’s esophagus,\2 cm, n (%) 1 (2)
Esophagitis (Los Angeles grade), n (%) 33 (55)
A, n (%) 5 (5)
B, n (%) 28 (95)
Hill grade, n (%) 55 (92)
I, n (%) 7 (13)
II, n (%) 48 (87)
Hiatal hernia, n (%) 52 (87)
Axial length B1 cm, n (%) 17 (33)
Axial length[1 and B2 cm, n (%) 35 (67)
Greatest transverse dimension B1 cm, n (%) 17 (33)
Greatest transverse dimension[1 and B2 cm, n (%) 35 (67)
Patients on single dose of PPI at entry, n (%)a 43 (72)
Patients on omeprazole at entry, n (%) 26 (43)
Patients on esomeprazole at entry, n (%) 17 (28)
Patients on lansoprazole at entry, n (%) 6 (10)
Patients on pantoprazole at entry, n (%) 7 (12)
Patients on dexlansoprazole at entry, n (%) 4 (7)
a Of 12 patients in the TF group who were taking double-dose PPIs at entry, 6 (50 %) patients were on
omeprazole; 3 (25 %) on pantoprazole; 2 (17 %) on lansoprazole; and 1 (8 %) on esomeprazole. In the PPI
group, of five patients who were taking double-dose PPIs, 3 (60 %) patients were on esomeprazole and 2
(40 %) were on omeprazole
Surg Endosc
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Of patients available for 1-, 2-, and 3-year follow-ups,
98 % (59/60) underwent endoscopic evaluation at 1-year,
91 % (50/55) at 2-year, and 79 % (41/52) at 3-year follow-
up. Esophagitis was diagnosed in 55 % (33/60) of patients
at pre-TF screening, in 5 % (3/59) at 1-year, in 10 % (5/50)
at 2-year, and in 12 % (5/41) of patients at 3-year follow-
up. Of 33 patients with esophagitis at screening,
esophagitis healed in 94 % (31/33) with one patient pre-
senting new onset grade A esophagitis at 1 year. At 2-year
follow-up, esophagitis healed in 93 % (26/28) of patients;
three patients presented with new onset of esophagitis
compared to screening (two grade A and one grade B). At
3-year follow-up, esophagitis healed in 86 % (19/22); two
patients who had esophagitis at 2 years were noted to have
persistent esophagitis.
Seventy-eight percent of patients (47/60) were com-
pletely off PPI therapy at 1 year, 76 % (42/55) at 2 years,
and 71 % of patients (37/52) had maintained their total
discontinuation of PPI therapy at 3 years post-TF. The
proportion of patients resuming PPI therapy did not change
significantly from 22 % at 1 year to 24 % at 2 years, and to
29 % at 3 years post-TF (p[ 0.05).
All esophageal pH parameters, with the exception of
duration of longest reflux, improved significantly at 1 year
post-TF as compared to screening and then remained
stable through the duration of the study (Table 4). The
improvement observed in duration of the longest reflux
episode was statistically significant at 2- and 3-year follow-
ups compared to screening. Rates of pH normalization
were similar at 1 (41 %, 24/59), 2 (37 %, 18/49), and
3 years (40 %, 16/40) post-TF.
Two percent of patients (1/60) at screening were satis-
fied with their current health condition as assessed by the
GERD-HRQL questionnaire on PPIs. At 1-, 2-, and 3-year
follow-ups, 76 % (44/58), 84 % (43/51), and 81 % (35/43)
of patients were satisfied with present health condition off
PPIs (p values\0.001, vs. screening on PPIs).
Discussion
This 3-year report represents the longest follow-up on the
TF procedure performed with the EsophyX device in the
USA to date. In addition to quality of life assessments, it
included analyses of variations over time in physiologic
parameters, endoscopic evaluation of healing esophagitis,
as well as rates of complete PPI discontinuation following
the procedure. Perhaps most importantly, it addresses
concerns about the durability of the outcomes after the TF
procedure, which is relevant given the historical context of
the poor long-term results of first-generation endoscopic
plication devices such as the Endo-Cinch and the NDO
Plicator [13]. Our study demonstrated that the TF proce-
dure results in sustained, significant, and clinically mean-
ingful elimination of troublesome GERD symptoms,
healing of reflux esophagitis, and improvements in all pH
parameters. The authors of this study believe that the
quality of the data offers reassurance as to the prolonged
benefits of TF up to 3 years post-procedure.
In addition to durable elimination of troublesome
regurgitation and atypical symptoms, our primary outcome
measure, this study provides evidence that the TF proce-
dure is effective in the sustained elimination of
Fig. 2 A Total regurgitation scores as evaluated by the Reflux
Disease Questionnaire before and after transoral fundoplication in
patients completing the study follow-up visits. B Reflux Disease
Questionnaire total score before and after transoral fundoplication in
patients completing the study follow-up visits
Fig. 3 Reflux Symptom Index (RSI) scores in patients completing
the study visits. Green line represents the normality threshold of 13
for the total RSI score
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troublesome heartburn, as evaluated by the GERD-HRQL
(Fig. 4). Furthermore, prolonged healing of reflux
esophagitis (86 % at 3 years) in this study and significant
improvements in all pH parameters recorded over 48-h
(Table 4) provide additional proof of the durability of the
TF procedure. A disconnect (by a factor of 2:1) between
the high rates of elimination of troublesome symptoms and
the normalization rates of EAE achieved in this study may
be viewed as problematic by some. It is important to note
that several studies evaluating TF [15, 19], PPI therapy
[20], and traditional laparoscopic fundoplication [21, 22]
have demonstrated poor correlation between post-treatment
pH parameters and symptom control as evaluated with
various disease-specific symptom scores [13].
While elimination of troublesome symptoms and heal-
ing of reflux esophagitis are well-established and clinically
relevant goals of GERD treatment [1], our studies [14, 15]
and a report by Hunter et al. [13] suggest that symptom
control may not require pH normalization. In fact, PPI
therapy may be less effective in controlling abnormal EAE
in certain patients than previously thought [15]. The rate of
pH normalization off PPIs noted in our study 3 years post-
TF (40 %) is comparable to rates of pH normalization
reported in patients on double-dose PPI therapy (approxi-
mately 50 %) [20, 23]. These observations raise two
important questions for future research. First, how much of
pH improvement is necessary to achieve adequate symp-
tom control and acceptable patient satisfaction? Second,
does pH normalization have complementary effects on
overall control of GERD? Uncontrolled GERD symptoms
are a major reason for patients to visit their physicians and
to utilize healthcare resources. We believe that the GERD
therapies that are safe and able to provide control of GERD
symptoms and prevent complications may reduce total
medical and societal costs associated with the treatment of
symptomatic GERD by reducing the frequency of outpa-
tient visits and improving work productivity.
The published literature suggests that achievement of
higher normalization rates of EAE after traditional anti-
reflux surgery may be attributed to the creation of a supra-
competent valve in such procedures; this may contribute to
troublesome and sometimes debilitating dysphagia and
bloating [13]. This is not the case in patients who receive
the TF procedure, as de novo occurrence of post-procedure
dysphagia and bloating is virtually nonexistent [14, 15, 24].











p value (3 years off PPIs vs.
screening on or off PPIs)
Hoarseness 1.9 (1.6) 2.5 (1.5) 0.6 (1.2) 0.6 (1.2) 0.4 (0.9) \0.0001
Throat clearing 2.9 (1.3) 3.3 (1.2) 0.9 (1.3) 1.1 (1.3) 0.6 (1.2) \0.0001
Excess throat mucus or post-nasal
drip
3.0 (1.4) 3.3 (1.2) 1.1 (1.3) 0.7 (1.2) 0.7 (1.3) \0.0001
Difficulty swallowing foods, liquids,
or pills
2.0 (1.4) 2.3 (1.5) 0.5 (0.9) 0.3 (0.8) 0.2 (0.6) \0.0001
Coughing after eating or after lying
down
2.4 (1.6) 2.9 (1.5) 0.6 (1.1) 0.7 (1.3) 0.5 (1.1) \0.0001
Breathing difficulties or choking
episodes
1.7 (1.6) 2.0 (1.5) 0.4 (0.9) 0.3 (0.6) 0.1 (0.4) \0.0001
Troublesome or annoying cough 2.2 (1.5) 2.8 (1.6) 0.7 (1.3) 0.5 (1.1) 0.3 (0.9) \0.0001
Sensation of something sticking or a
lump in the throat (globus)
2.7 (1.4) 2.9 (1.4) 0.7 (1.2) 0.7 (1.2) 0.5 (1.0) \0.0001
Heartburn, chest pain, indigestion or
stomach acid coming up
3.3 (1.4) 4.2 (1.0)a 1.1 (1.5) 1.2 (1.7) 0.7 (1.4) \0.0001
Values represent means (SDs)
a p values between 1-, 2-, and 3-year follow-ups[0.05 in all cases except (p = 0.0038)
Fig. 4 Gastroesophageal reflux disease health-related quality of life
(GERD-HRQL) scores through the duration of study
Surg Endosc
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The results of the 6- and 12-month follow-ups of the
TEMPO trial comparing TF with high-dose PPIs had
established the superiority of TF in controlling regurgita-
tion, heartburn, and atypical symptoms in a subgroup of
chronic GERD patients with small (\2 cm) or absent hiatal
hernias and with incomplete responses to PPIs [14, 15].
Similar results were reported in two other double-blinded
randomized trials, one of which compared TF and placebo
pills versus sham procedure and high-dose PPIs [13] and
another comparing TF versus sham procedure in a Euro-
pean population [12].
The cohort of patients considered for our report con-
sisted of the totality of patients enrolled in the TEMPO
trial, merging the group originally randomized to TF with
the initial high-dose PPI control group (of which all
patients elected to undergo crossover TF). Both groups
were statistically similar in every respect, allowing for this
design [15].
All TF procedures in this study were completed without
perioperative or long-term SAE reported, underscoring the
safety of the procedure. There have been more than 17,000
procedures performed worldwide to date, without mortality
and with an estimated SAE rate of 3.4 % in the published
literature [24]. In this study, there were two reoperations
(3 %); these patients were considered as failures of TF and
included as such in our statistical analysis. Both revisional
operations were performed without difficulty, confirming
previous reports on the safety and feasibility of laparo-
scopic anti-reflux surgery after TF [25]. Recently, a study
discussing another more invasive anti-reflux procedure
purported that the rate of reoperation following TF could
range from 11.5 to 52.6 % [26], citing reports from Europe
where earlier iterations of the device and technique had
been used [27–30] in a suboptimally selected patient pop-
ulation which included large hiatal hernias and Hill grade
III and IV. In contrast, in the TEMPO trial and other recent
randomized controlled TF trials [12–15], all patients
received a standardized TF 2.0 procedure with a rotational
component, as described by Bell and Cadière [11]. Further,
TEMPO participants deployed 21 fasteners on average, in
accordance with previous reports indicating a direct cor-
relation between the number of fasteners and the durability
of favorable outcomes [31]. Lastly, the quality of our
results can be attributed to the adherence to strict selection
criteria, particularly by excluding patients with hiatal her-
nias larger than 2 cm in either axial height or greatest
transverse dimension, patients with Hill grade III or IV
ratings of the GEJ, and patients with more severe erosive
esophagitis (Los Angeles grade C or D).
We report in this study complete discontinuation of PPI
use in 71 % of patients 3 years after TF, without statisti-
cally significant change compared to PPI cessation rates at
1- and 2-year follow-ups in the same group of patients.
Testoni et al. [32] had reported that the percentage of
patients who either stopped or halved their PPI therapy at
3-year follow-up was unchanged at 6 years (84 %), which
portends positively for maintaining even longer-term PPI
cessation rates in the same range. Interestingly, in the same
study, complete discontinuation of PPIs dropped from
61 % of patients at 6 months to 30 % at 6 years, with the
sharpest drop observed between 6 and 12 months post-TF,
indicating that resumption of PPIs was most common
within the first year after the procedure. In our view, this
underscores the importance of patient selection and good
technique. Furthermore, various factors make PPI use after
any anti-reflux procedure an unreliable measure of success
or failure, including easy access to over-the-counter med-
ications and patients’ tendencies to resume PPI use without
objective documentation of GERD. In fact, PPIs may be
viewed an acceptable adjunct to TF procedures in patients









p values (all intervals
vs. screening)
p values (between 1-, 2-, and
3-year follow-ups)
Number of refluxes 169.8 (80.0) 117.1 (61.8) 106.6 (50.8) 105.1 (72.8) B0.0002 C0.8201
Number of long
refluxes ([5 min)
12.5 (6.2) 10.2 (7.2) 10.3 (8.1) 8.9 (7.4) \0.0001 C0.9763
Duration of longest
reflux (min)
29.4 (15.0) 24.2 (14.8) 20.2 (23.4) 18.6 (19.1) * C0.4298
Fraction time pH\4
(%)
10.5 (3.5) 7.6 (4.6) 7.7 (5.1) 7.8 (5.7) B0.0283 C0.9944
DeMeester score 36.0 (12.2) 26.5 (15.2) 26.3 (16.3) 26.9 (18.2) B0.0173 C0.9981
The values represent the total means (SD) based on 48-h pH testing
* p values: 3 years versus screening = 0.0171, 2 years versus screening = 0.0384, 1 year versus screening = 0.3794
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whose GERD symptoms were uncontrolled on high-dose
PPIs preoperatively [14, 15].
Limitations of the current study include its open-label,
crossover design that may introduce a potential bias. While
a comparison at 3 years of the medical (PPI) group and the
TF group might have offered valuable additional data,
there are several reasons for using a crossover design.
Following enrollment, patients in the PPI group were
required to take the maximum standard dose of currently
used PPI in an attempt to optimize control of their GERD
symptoms [14]. Patients experiencing ongoing symptoms
despite medical therapy are routinely stepped up to maxi-
mum dosage in an attempt to control troublesome symp-
toms. Furthermore, the recommended treatment for
patients with predominant extraesophageal symptomatol-
ogy (our study population) is aggressive acid reduction
using PPIs twice daily short term over a duration of
3–4 months [33]. A 3-year comparison between two groups
would have likely made enrollment of patients and perhaps
IRB approval very difficult. Furthermore, we elected to
utilize a crossover design rather than analyzing two parallel
groups to eliminate any potential confounding factors that
may influence clinical outcomes [14]. Primarily, the
TEMPO study was designed to evaluate efficacy of TF
versus high-dose PPI therapy at 6- and 12-month follow-
ups and secondarily to assess a durability of TF in all
patients who underwent the TF procedure. Therefore, for
the long-term outcomes each patient served as his/her own
control. While we recognize that 11 patients were lost to
follow-up for the 3-year evaluation, we believe that an
attrition rate of 17 % is acceptable for any 3-year follow-up
study. Additionally, as commonly seen in studies evaluat-
ing GERD therapies, not all patients were willing to
undergo objective evaluation at the study intervals
(Table 4); however, the consistent results between 1-, 2-,
and 3-year follow-ups from this study, combined with the
evidence from double-blind randomized studies [12, 13]
and from the long-term European study [32], further sup-
port the safety, efficacy, and durability of TF. We conclude
that TF offers chronic GERD patients with incomplete
symptom control on PPI therapy an effective therapeutic
alternative with lasting effect.
A study designed to provide a direct randomized com-
parison of the traditional anti-reflux surgery and the TF
would be very difficult to enroll. Traditional anti-reflux
surgery is often reserved for the patients with the most
severe GERD, including patients with large hiatal hernias.
In such patients, a diaphragmatic crural closure is routinely
performed. In contrast, the use of the EsophyX device to
perform the endoscopic TF procedure is restricted to a
well-selected subset of GERD patients with small (B2 cm)
or absent hiatal hernia. This is reflected in the selection
criteria of the TEMPO trial. Such patients are not typically
referred for a surgical fundoplication; these patients receive
a dose escalation of PPIs and addition of H2 blockers for
breakthrough symptoms. In the case–control study of
patients undergoing TF, Nissen, or Toupet fundoplication,
TF achieved similar dramatic symptom resolution, when
compared to Nissen or Toupet fundoplication; a shorter
operative times and lengths of stay were observed after TF
[34]. The TEMPO trial offered a randomized comparison
of the two options for a common clinical scenario which
presents significant challenges; it was conducted to find out
whether TF is a viable alternative to patients with incom-
plete symptom control on optimized PPI therapy and who
are fearful of the potential side effects of fundoplication.
Furthermore, the level of scientific proof of its efficacy and
therapeutic gain surpasses anything currently available
outside the area of traditional laparoscopic anti-reflux
surgery [12]. Based on currently available evidence, the
authors believe that the TF procedure performed with the
EsophyX device should not be considered experimental
and should be offered to well-selected chronic GERD
patients.
Conclusion
Our study demonstrated that the transoral esophagogastric
fundoplication procedure performed with the EsophyX
device provides sustained symptomatic relief, healing of
reflux esophagitis, and prolonged improvement in all eso-
phageal pH parameters at 3-year follow-up. Our results
further confirm the safety, efficacy, and durability of TF in
well-selected symptomatic GERD patients on chronic PPI
therapy. We conclude that transoral fundoplication should
be considered in the management of GERD patients with
similar disease characteristics as presented in this study.
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